AZ pays $50m for Merck’s cancer drug
AstraZeneca and Merck & Co (known as MSD outside the US and Canada) have entered into a worldwide licensing agreement for Merck’s oral small molecule inhibitor of WEE1 kinase (MK-1775). MK-1775 is currently being evaluated in phase 2 clinical trials in combination with standard of care therapies for the treatment of patients with certain types of ovarian cancer.
Under the terms of the agreement, AstraZeneca will pay Merck a US $50 million upfront fee. Merck will also be eligible to receive future payments tied to development and regulatory milestones plus sales-related payments and tiered royalties. AstraZeneca will be responsible for all future clinical development, manufacturing and marketing.
Susan Galbraith, Head of AstraZeneca’s Oncology Innovative Medicines Unit.
Iain D. Dukes, senior vice president and head of licensing and external scientific affairs at Merck.
The agreement is contingent to customary closing conditions.
AstraZeneca pays $50 million for rights to Merck cancer drug (Economic Times)
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.